Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NAVB Navidea Biopharmaceuticals	$0.00	$0.00	$0.00 ▼ $0.13	$50K	1.71	7,715 shs	1,666 shs
SMFL Smart for Life	$0.00 -58.1%	$0.01	$0.00 ▼ $2.58	$18K	17.05	6,389 shs	1,143 shs
SYRS Syros Pharmaceuticals	$0.00	$0.01	$0.00 ▼ $0.10	$43K	1.31	191,767 shs	7,657 shs
VINC Vincerx Pharma	$0.04 +0.8%	$0.05	$0.03 ▼ $17.00	$204K	1.71	582,452 shs	41,731 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NAVB Navidea Biopharmaceuticals	0.00%	0.00%	+400.00%	-28.57%	-50.00%
SMFL Smart for Life	0.00%	+181.82%	-70.05%	+3,000.00%	-99.31%
SYRS Syros Pharmaceuticals	0.00%	+45.45%	-84.00%	-94.72%	-99.89%
VINC Vincerx Pharma	0.00%	-2.76%	-14.38%	-19.54%	-99.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SMFL Smart for Life	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SYRS Syros Pharmaceuticals	4.3925 of 5 stars	3.0	5.0	0.0	4.3	2.2	2.5	0.6
VINC Vincerx Pharma	2.7171 of 5 stars	3.5	3.0	0.0	0.0	1.1	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NAVB Navidea Biopharmaceuticals	0.00	N/A	N/A	N/A
SMFL Smart for Life	0.00	N/A	N/A	N/A
SYRS Syros Pharmaceuticals	2.00	Hold	$1.00	62,400.00% Upside
VINC Vincerx Pharma	3.00	Buy	$40.00	102,464.10% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NAVB Navidea Biopharmaceuticals	$8.13K	6.16	N/A	N/A	N/A	∞
SMFL Smart for Life	$11.11M	0.00	N/A	N/A	($17.10) per share	0.00
SYRS Syros Pharmaceuticals	$386K	0.11	N/A	N/A	$0.79 per share	0.00
VINC Vincerx Pharma	N/A	N/A	N/A	N/A	$10.50 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NAVB Navidea Biopharmaceuticals	-$15.18M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
SMFL Smart for Life	-$22.68M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
SYRS Syros Pharmaceuticals	-$164.57M	-$3.03	N/A	N/A	N/A	N/A	-3,369.56%	-97.04%	10/29/2025 (Estimated)
VINC Vincerx Pharma	-$40.16M	-$20.60	N/A	N/A	N/A	N/A	-248.33%	-132.73%	8/19/2025 (Estimated)

Latest NAVB, VINC, SMFL, and SYRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
6/11/2025	Q3 2024	SMFL Smart for Life	N/A	-$0.94	N/A	-$0.94	N/A	$1.27 million
5/23/2025	Q2 2024	SMFL Smart for Life	N/A	-$2.41	N/A	-$2.34	N/A	$0.88 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
SMFL Smart for Life	N/A	N/A	N/A	N/A	N/A
SYRS Syros Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VINC Vincerx Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A
SMFL Smart for Life	N/A	N/A	N/A
SYRS Syros Pharmaceuticals	N/A	2.25	2.25
VINC Vincerx Pharma	N/A	2.17	2.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NAVB Navidea Biopharmaceuticals	0.01%
SMFL Smart for Life	28.39%
SYRS Syros Pharmaceuticals	91.47%
VINC Vincerx Pharma	44.02%

Insider Ownership

Company	Insider Ownership
NAVB Navidea Biopharmaceuticals	43.68%
SMFL Smart for Life	31.71%
SYRS Syros Pharmaceuticals	12.26%
VINC Vincerx Pharma	15.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NAVB Navidea Biopharmaceuticals	10	100.08 million	56.37 million	Optionable
SMFL Smart for Life	110	7.09 million	4.84 million	Not Optionable
SYRS Syros Pharmaceuticals	120	26.83 million	23.54 million	Optionable
VINC Vincerx Pharma	60	5.23 million	1.89 million	Not Optionable

NAVB, VINC, SMFL, and SYRS Headlines

Recent News About These Companies

Vincerx Pharma (NASDAQ:VINC) vs. NovaBay Pharmaceuticals (NYSE:NBY) Head to Head Survey

August 8, 2025 | americanbankingnews.com

Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders ...

July 16, 2025 | gurufocus.com

Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution Proposal

July 16, 2025 | globenewswire.com

Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders | The ... - The Manila Times

July 9, 2025 | manilatimes.netM

Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders - Morningstar

July 9, 2025 | morningstar.comM

Vincerx Pharma, Inc. Common Stock (VINC) - Yahoo Finance

July 8, 2025 | finance.yahoo.com

Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders

July 7, 2025 | globenewswire.com

Vincerx Pharma, Inc. (VINC) - Yahoo Finance

July 2, 2025 | ca.finance.yahoo.com

Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal

June 18, 2025 | globenewswire.com

Vincerx Pharma announces plan to delist from Nasdaq

April 18, 2025 | markets.businessinsider.com

Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC

April 17, 2025 | finance.yahoo.com

Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC

April 17, 2025 | globenewswire.com

Vincerx's final merger attempt collapses, leaving ADC biotech to wind down

April 9, 2025 | fiercebiotech.comF

Vincerx terminates letter of intent with Global Digital, initiates wind down

April 9, 2025 | markets.businessinsider.com

Financially struggling drugmaker's potential rescue falls apart. It now will wind down

April 9, 2025 | bizjournals.com

Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities

April 8, 2025 | globenewswire.com

Vincerx Pharma announces non-binding LOI for Qumulus AI combination

March 18, 2025 | markets.businessinsider.com

Vincerx Pharma, Inc.: Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI

March 18, 2025 | finanznachrichten.de

Vincerx, left in limbo by collapsed deal, moves to merge with AI company to escape cash crisis

March 18, 2025 | fiercebiotech.comF

Vincerx Pharma Shares Soar on Proposed Merger with Global Digital Holdings

March 18, 2025 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAVB, VINC, SMFL, and SYRS Company Descriptions

Navidea Biopharmaceuticals NYSE:NAVB

$0.0005 0.00 (0.00%)

As of 01:29 PM Eastern

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

Smart for Life NASDAQ:SMFL

$0.0026 0.00 (-58.06%)

As of 02:16 PM Eastern

Smart for Life, Inc. acquires, develops, manufactures, operates, markets, and sells nutraceutical and related products in the United States and internationally. It offers natural health and wellness meal replacement products, including nutrition bars, cookies, soups and shakes, vitamins, and supplements under the Smart for Life brand; dietary supplements; and nutritional products, including whey protein isolate powder, tablet supplements for joint health, nitric oxide, post workout blends, Omega-3 supplements, and pre-workout supplements under the Sports Illustrated Nutrition brand for athletes and active lifestyle consumers. The company also provides various nutritional products, including antioxidant rich supplements, plant-based proteins, alkalizing nutrients, and weight management products. It sells its products through online market platforms. The company was formerly known as Bonne Santé Group, Inc. and changed its name to Smart for Life, Inc. in August 2021. Smart for Life, Inc. was founded in 2002 and is based in Boca Raton, Florida.

Syros Pharmaceuticals NASDAQ:SYRS

$0.0016 0.00 (0.00%)

As of 01:47 PM Eastern

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Vincerx Pharma NASDAQ:VINC

$0.04 +0.00 (+0.78%)

As of 02:31 PM Eastern

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time